KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Intangibles (2020 - 2025)

AbCellera Biologics (ABCL) has disclosed Intangibles for 6 consecutive years, with $41.2 million as the latest value for Q1 2025.

  • For the quarter ending Q1 2025, Intangibles changed N/A year-over-year to $41.2 million, compared with a TTM value of $41.2 million through Mar 2025, changed N/A, and an annual FY2024 reading of $42.1 million, changed N/A over the prior year.
  • Intangibles was $41.2 million for Q1 2025 at AbCellera Biologics, down from $42.1 million in the prior quarter.
  • Across five years, Intangibles topped out at $163.0 million in Q3 2022 and bottomed at $41.2 million in Q1 2025.
  • Average Intangibles over 5 years is $114.9 million, with a median of $129.1 million recorded in 2022.
  • The sharpest move saw Intangibles rose 28.87% in 2021, then dropped 11.38% in 2022.
  • Year by year, Intangibles stood at $148.4 million in 2021, then decreased by 11.38% to $131.5 million in 2022, then dropped by 3.62% to $126.7 million in 2023, then crashed by 66.77% to $42.1 million in 2024, then decreased by 2.19% to $41.2 million in 2025.
  • Business Quant data shows Intangibles for ABCL at $41.2 million in Q1 2025, $42.1 million in Q4 2024, and $126.7 million in Q2 2023.